Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19920302 | 0.96 | GLS (0.79) | GLS | |
| SCHEMBL15042421 | 0.95 | GLS (0.84) | GLS | |
| SCHEMBL15042429 | 0.95 | GLS (0.84) | GLS | |
| SCHEMBL14987156 | 0.92 | GLS (1.00) | GLS | |
| SCHEMBL15042292 | 0.92 | GLS (1.00) | GLS | |
| SCHEMBL14987455 | 0.92 | GLS (1.00) | GLS | |
| SCHEMBL19920379 | 0.91 | GLS (0.80) | GLS | |
| SCHEMBL22030776 | 0.91 | GLS (0.90) | GLS | |
| SCHEMBL14986969 | 0.90 | GLS (1.00) | GLS | |
| SCHEMBL21368633 | 0.90 | GLS (1.00) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180055825-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | LIANG YU (US) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180055825-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.